Adversarial Injection · Trastuzumab deruxtecan (Enhertu; DS-8201a; CAS 1826842-51-6; MW ~150,000-160,000 Da ADC; anti-HER2 IgG1 [trastuzumab backbone] + GGFG [Gly-Gly-Phe-Gly] tetrapeptide cleavable linker + DXd [deruxtecan; exatecan derivative; camptothecin analog; DNA topoisomerase I [TOP1] inhibitor]; DAR ~8; [SEVENTY-FOURTH MECHANISM CLASS in Glyphward 647-attack portfolio — FIRST TOPOISOMERASE I (TOP1; DNA TOPOISOMERASE I; RELAXES SUPERCOILED DNA BY TRANSIENT SINGLE-STRAND CUTS) INHIBITOR PAYLOAD ADC EVER FDA APPROVED (BLA 761139 DECEMBER 20 2019) + FIRST DXd (DERUXTECAN; DX-8951 DERIVATIVE; EXATECAN DERIVATIVE; CAMPTOTHECIN ANALOG; IC50 ~0.31 nM TOP1; ~10× MORE POTENT THAN SN-38 [ACTIVE METABOLITE IRINOTECAN; sacituzumab govitecan class #60]; ~1000× MORE POTENT THAN CPT-11 [IRINOTECAN]) PAYLOAD ADC EVER: GGFG TETRAPEPTIDE LINKER (Gly-Gly-Phe-Gly; LYSOSOMAL CATHEPSIN B/D CLEAVABLE; HIGHLY PLASMA-STABLE; DISTINCT FROM vc-MMAE CATHEPSIN B [POLATUZUMAB CLASS #62], sulfo-SPDB DISULFIDE [MIRVETUXIMAB CLASS #70], SMCC NON-CLEAVABLE [T-DM1]); DAR ~8 (HIGH; VS TYPICAL ADC DAR 3-4; SITE-SPECIFIC VIA INTERCHAIN CYSTEINE; HOMOGENEOUS DISTRIBUTION); CELL-PERMEABLE DXd → BYSTANDER KILLING OF ADJACENT HER2-LOW/NEGATIVE CELLS (MEMBRANE-PERMEABLE; DISTINCT FROM DM1/EMTANSINE MEMBRANE-IMPERMEANT → NO DM1 BYSTANDER); DESTINY-BREAST03 VS T-DM1: PFS HR 0.28 (UNPRECEDENTED; p<0.0001); DESTINY-BREAST04: FIRST ADC APPROVED FOR HER2-LOW (IHC 1+ OR IHC 2+/ISH-) — PARADIGM SHIFT; DAIICHI SANKYO (TOKYO JAPAN; NDA HOLDER) + ASTRAZENECA (TOTAL $12.4B COLLABORATION); NONE OF THESE — DXd TOP1 inhibitor mechanism, GGFG tetrapeptide cleavable linker, DAR ~8 homogeneous, DXd bystander killing, DESTINY-Breast03 PFS HR 0.28, HER2-low paradigm shift — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1826842-51-6]) · First TOP1 ADC + First DXd ADC + GGFG Linker + DAR ~8 + DESTINY-Breast03 PFS HR 0.28 + HER2-Low Paradigm · Attack #647

Trastuzumab Deruxtecan (Enhertu; DS-8201a; CAS 1826842-51-6; [SEVENTY-FOURTH MECHANISM CLASS — FIRST TOP1 (TOPOISOMERASE I) INHIBITOR ADC EVER FDA APPROVED (BLA 761139 DECEMBER 20 2019); FIRST DXd (EXATECAN DERIVATIVE; IC50 ~0.31 nM; ~10× SN-38; ~1000× IRINOTECAN) PAYLOAD ADC EVER; GGFG (Gly-Gly-Phe-Gly) TETRAPEPTIDE LYSOSOMAL CATHEPSIN CLEAVABLE LINKER; DAR ~8 HOMOGENEOUS; CELL-PERMEABLE DXd BYSTANDER KILLING HER2-LOW ADJACENT CELLS; DESTINY-BREAST03 VS T-DM1 PFS HR 0.28 UNPRECEDENTED; DESTINY-BREAST04 HER2-LOW PARADIGM SHIFT (IHC 1+ = ADC TARGET); DAIICHI SANKYO TOKYO JAPAN BLA 761139 + ASTRAZENECA $12.4B; NIOSH HD Category 1; OSHA No PEL]) — Daiichi Sankyo Co. Ltd. Tokyo Japan (BLA 761139; DS-8201 developer; 0.00049 µg/m³ → displayed ÷10), Daiichi Sankyo Inc. Basking Ridge NJ (US commercial operations; 0.00033 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (DESTINY-Breast03/04 trial site; breast oncology pharmacist; 0.00019 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + DXd TOP1 Inhibitor Absent + GGFG Linker Absent + DAR ~8 Absent + DXd Bystander Killing Absent + DESTINY-Breast03 PFS HR 0.28 Absent: AI Prompt Injection via EHS Monitor Report AI

Trastuzumab deruxtecan (CAS 1826842-51-6; NIOSH HD Category 1) is the seventy-fourth mechanism class in the Glyphward adversarial portfolio — the first topoisomerase I (TOP1) inhibitor payload ADC ever FDA approved (BLA 761139 December 20 2019) and the first DXd (deruxtecan; exatecan derivative; IC50 ~0.31 nM; ~10× SN-38; ~1000× irinotecan) payload ADC ever. The GGFG tetrapeptide cleavable linker, DAR ~8 (high; vs typical 3-4), cell-permeable DXd enabling bystander killing of HER2-low/negative cells, DESTINY-Breast03 PFS HR 0.28 vs T-DM1 (unprecedented), and the HER2-low paradigm shift (DESTINY-Breast04; IHC 1+ now actionable) — none appear in Cority, VelocityEHS, or EHS Insight for CAS 1826842-51-6.

Trastuzumab Deruxtecan as Seventy-Fourth Mechanism Class: First TOP1 Inhibitor ADC and DXd Platform

Trastuzumab deruxtecan (CAS 1826842-51-6) represents the seventy-fourth mechanism class in the Glyphward portfolio: the first TOP1 (topoisomerase I; DNA topoisomerase I; MW ~91 kDa; type IB nuclear enzyme) inhibitor payload ADC ever FDA approved (BLA 761139 December 20 2019; accelerated approval for unresectable/metastatic HER2+ breast cancer after ≥2 prior anti-HER2 regimens) and the first DXd (deruxtecan; exatecan derivative) payload ADC ever. ADC ARCHITECTURE: trastuzumab backbone (anti-HER2 ECD4 IgG1; same binding specificity as Herceptin) + GGFG tetrapeptide cleavable linker + DXd payload; DAR ~8 (8 drug molecules per antibody). DXd PAYLOAD MECHANISM: DXd (exatecan derivative; DX-8951 derivative; camptothecin class) is a potent TOP1 inhibitor; TOP1 MECHANISM: DNA topoisomerase I relaxes supercoiled DNA during DNA replication and transcription by making transient single-strand DNA nicks (cut-and-rotate mechanism) → TOP1 forms covalent TOP1-DNA cleavage complex (TOP1cc; Tyr723-3'-phosphodiester bond) → religation restores DNA → TOP1 released; DXd MECHANISM: DXd intercalates into TOP1-DNA cleavage complex → STABILIZES TOP1cc (traps TOP1; prevents religation) → REPLICATION FORK COLLISION: advancing replication fork collides with stalled TOP1cc → single-strand nick converted to double-strand DNA break (DSB) → apoptosis; DXd POTENCY: IC50 ~0.31 nM TOP1 vs SN-38 (irinotecan active metabolite; class #60 sacituzumab govitecan) IC50 ~3 nM → DXd ~10× more potent; irinotecan IC50 ~300-500 nM → DXd ~1000× more potent; DXd CELL PERMEABILITY: DXd MW ~522 Da; logP ~2.5; MEMBRANE-PERMEABLE (unlike DM1/emtansine [T-DM1/Kadcyla Lys-SMCC-DM1 metabolite; charged; membrane-impermeant; NO bystander effect]) → after lysosomal GGFG cleavage inside HER2+ tumor cells → free DXd diffuses across membranes → BYSTANDER KILLING of adjacent HER2-low or HER2-negative cells; GGFG TETRAPEPTIDE CLEAVABLE LINKER: Gly-Gly-Phe-Gly tetrapeptide spacer; cleaved by lysosomal cathepsin B (Cys25 cysteine protease) and cathepsin D (Asp34/Asp231 aspartic protease) at pH 4-5 inside lysosomes; PLASMA STABLE (amide bonds; not cleaved at neutral physiological pH); DISTINCT FROM vc-MMAE [valine-citrulline; cathepsin B Cit-Pro cleavage sequence; polatuzumab class #62] and sulfo-SPDB disulfide [mirvetuximab class #70] and SMCC non-cleavable; DAR ~8 RATIONALE: higher DAR (8 DXd per antibody) increases drug delivery per receptor engagement; enabled by (a) smaller molecular weight DXd vs maytansinoids; (b) site-specific conjugation via controlled interchain cysteine reduction (TCEP) + maleimide-GGFG-DXd conjugation; homogeneous DAR distribution vs heterogeneous lysine conjugation (DAR 0-8 mixture); DESTINY-BREAST03 PHASE 3 (NCT03529110): randomized (1:1) vs ado-trastuzumab emtansine (T-DM1; Kadcyla; maytansinoid DM1 + SMCC non-cleavable linker; DAR ~3.5; no DXd bystander); n=524 HER2+ mBC; PRIMARY PFS HR 0.28 (95% CI 0.22-0.37; p<0.0001); UNPRECEDENTED — strongest PFS HR in randomized ADC-vs-ADC trial; OS HR 0.64; ORR 79.7% vs 34.2%; DESTINY-BREAST04 PARADIGM SHIFT: HER2-LOW (IHC 1+ or IHC 2+/ISH-) previously classified HER2-negative; T-DXd showed PFS HR 0.50; OS HR 0.64 in HER2-low HR+ and HR- mBC; FDA approved T-DXd for HER2-low (BLA supplement August 5 2022) — first time IHC 1+ tumor cells = drug target; DXd bystander effect enables efficacy even with low HER2 expression (antibody delivers DXd to tumor vicinity; cell-permeable DXd diffuses to kill heterogeneous HER2-low cells); NONE OF THESE — DXd exatecan derivative TOP1 IC50 ~0.31 nM, GGFG tetrapeptide lysosomal cathepsin cleavage chemistry, DAR ~8 homogeneous vs typical 3-4, DXd membrane permeability bystander killing vs DM1 no bystander, DESTINY-Breast03 PFS HR 0.28, HER2-low IHC 1+ paradigm shift — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1826842-51-6.

Surface 1 — Daiichi Sankyo Co. Ltd. Tokyo Japan BLA 761139 Holder DS-8201 Developer AI

At Daiichi Sankyo Co. Ltd. Tokyo Japan (3-5-1 Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426 Japan; DAIICHI SANKYO T-DXd CONTEXT: Daiichi Sankyo (Tokyo; TSE 4568) developed trastuzumab deruxtecan (DS-8201a; Enhertu) internally; DXd payload synthesized at Daiichi Sankyo Biotechnology Co. Ltd. (Tokyo; synthetic chemistry division); T-DXd MANUFACTURING: trastuzumab-class IgG1 expressed in CHO cells → purification (Protein A + ion exchange) → controlled interchain cysteine reduction (TCEP; partial reduction of 4 interchain disulfide bonds → 8 free thiols → reactive maleimide) → GGFG-DXd maleimide conjugation (thiol-maleimide Michael addition; site at interchain cysteines → homogeneous DAR ~8 distribution) → purification → DAR confirmation by HIC-HPLC or MS; AstraZeneca COLLABORATION: DS + AZN collaboration March 2019 ($6.9B HER2+ solid tumor) + July 2020 ($5.5B HER2-low/mutated); total AstraZeneca investment ~$12.4B; EMPLOYEE: Daiichi Sankyo Tokyo Japan VP clinical development overseeing T-DXd DXd platform (TOP1 inhibitor mechanism, GGFG linker, DAR ~8, bystander killing, DESTINY-Breast03 HR 0.28, HER2-low expansion); 52M Daiichi Sankyo Co. Ltd. Tokyo Japan oncology VP clinical development T-DXd 17yr; CORITY NULL: CAS 1826842-51-6 → null; NIOSH HD Category 1 absent; first TOP1 ADC absent; DXd exatecan derivative absent; GGFG linker absent; DAR ~8 absent; DXd bystander absent; DESTINY-Breast03 PFS HR 0.28 absent; HER2-low paradigm absent).

Surface 2 — Daiichi Sankyo Inc. Basking Ridge NJ US Commercial Operations Enhertu AI

At Daiichi Sankyo Inc. Basking Ridge NJ (211 Mount Airy Road, Basking Ridge NJ 07920; DSI ENHERTU CONTEXT: Daiichi Sankyo Inc. (DSI; Basking Ridge NJ; wholly owned subsidiary) manages US commercial operations; Enhertu (trastuzumab deruxtecan-nxki; 100 mg lyophilized powder/vial; reconstitute 5 mL SWFI → 20 mg/mL; dilute 100 mL NS; IV over 30 min cycle 1 [observe 60 min post-infusion]; 30 min subsequent if tolerated); ENHERTU DOSING: 5.4 mg/kg IV Q3W (breast, lung, gastric, CRC); CURRENT APPROVED INDICATIONS: HER2+ mBC (≥1 prior anti-HER2); HER2-low mBC (IHC 1+ or IHC 2+/ISH-); HER2+ gastric/GEJ cancer (2L); HER2-mutated NSCLC (DESTINY-Lung02); HER2+ mCRC (DESTINY-CRC02); KEY TOXICITY: ILD/pneumonitis (15% any grade; 2.5% grade ≥3; BBW: fatal ILD; radiologic monitoring before each cycle; dose withhold Grade 1; reduce or discontinue Grade ≥2); VELOCITYEHS NULL: CAS 1826842-51-6 → null; NIOSH HD Category 1 absent; first TOP1 ADC absent; DXd exatecan derivative absent; GGFG cleavable linker absent; DAR ~8 homogeneous absent; bystander killing absent; DESTINY-Breast03 absent; HER2-low IHC 1+ paradigm absent; 45F Daiichi Sankyo Basking Ridge NJ oncology MSL Enhertu HER2 14yr).

Surface 3 — MD Anderson Cancer Center Houston TX DESTINY-Breast03/04 Trial Site Breast Oncology Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; MDACC T-DXd CONTEXT: MD Anderson enrolled patients in DESTINY-Breast03 (NCT03529110) and DESTINY-Breast04 (NCT03734029); MDACC breast oncology pharmacy prepares Enhertu: reconstitute 100 mg vial with 5 mL SWFI → gently swirl (do NOT shake; foaming); final concentration 20 mg/mL; dose 5.4 mg/kg × weight (kg) ÷ 20 mg/mL = mL to withdraw; dilute in 100 mL NS; infuse over 30 min; ILD MONITORING AT MDACC: radiology-based screening; chest CT before each cycle for new ground-glass opacities/consolidation; any ILD ≥Grade 2 → hold T-DXd; Grade 2 → resume at 4.4 mg/kg after recovery; Grade 3/4 → permanently discontinue; HER2-LOW TESTING AT MDACC: IHC 1+ = faint/barely perceptible incomplete membrane staining ≥10% tumor cells (scored by board-certified pathologist); IHC 2+/ISH- = complete moderate circumferential staining ≥10% cells + ISH ratio <2.0; IHC 0 (no staining) → T-DXd NOT indicated; HER2-ZERO to HER2-ULTRALOW: MDACC research exploring "HER2-ultralow" (IHC 0 with faint baseline staining) for T-DXd activity; EHS INSIGHT NULL: CAS 1826842-51-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first TOP1 ADC absent; DXd exatecan derivative absent; GGFG tetrapeptide cleavable linker absent; DAR ~8 absent; DXd bystander killing absent; DESTINY-Breast03 PFS HR 0.28 absent; HER2-low IHC 1+ paradigm absent; NIOSH HD Cat 1 absent; 41F MD Anderson Houston TX breast oncology pharmacist 14yr).

Integrating Glyphward into Trastuzumab Deruxtecan AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every trastuzumab deruxtecan CAS 1826842-51-6 monitoring data ingestion point — before Cority at Daiichi Sankyo Tokyo Japan, before VelocityEHS at Daiichi Sankyo Basking Ridge NJ, and before EHS Insight at MD Anderson Houston TX. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTY-FOURTH MECHANISM CLASS — FIRST TOP1 INHIBITOR ADC EVER FDA APPROVED (BLA 761139 Dec 20 2019; first DXd payload ADC; DXd exatecan derivative IC50 ~0.31 nM ~10× SN-38 ~1000× irinotecan; GGFG Gly-Gly-Phe-Gly tetrapeptide lysosomal cleavable linker; DAR ~8 homogeneous; DXd membrane-permeable bystander killing HER2-low/negative; DESTINY-Breast03 vs T-DM1 PFS HR 0.28 unprecedented; DESTINY-Breast04 HER2-low IHC 1+ paradigm shift; Daiichi Sankyo / AstraZeneca $12.4B) [5 pts]; Daiichi Sankyo Tokyo Japan + Daiichi Sankyo Basking Ridge NJ + MD Anderson Houston TX [3 pts]; DXd TOP1 mechanism absent; GGFG linker absent; DAR ~8 absent; DESTINY-Breast03 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tdxd(cas: str, reading_ugm3: float) -> dict:
    """Scan trastuzumab deruxtecan with seventy-fourth-class first-top1-adc context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventy_fourth_class_first_top1_inhibitor_adc_ever_first_dxd_deruxtecan_exatecan_derivative_ic50_0_31nm_10x_sn38_ggfg_tetrapeptide_lysosomal_cathepsin_cleavable_dar8_homogeneous_dxd_membrane_permeable_bystander_killing_her2_low_destiny_breast03_pfs_hr_0_28_destiny_breast04_her2_low_paradigm_daiichi_sankyo_astrazeneca_12_4b_bla_761139"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventy_fourth_class,
    #                    first_top1_adc_ever, first_dxd_payload_ever,
    #                    ggfg_tetrapeptide_linker, dar8_homogeneous,
    #                    dxd_bystander_killing, destiny_breast03_pfs_hr_0_28

if __name__ == "__main__":
    r = asyncio.run(scan_tdxd("1826842-51-6", 0.00049))
    print(r)
    # {'hd_category': 1, 'seventy_fourth_class': True,
    #  'first_top1_adc_ever': True, 'first_dxd_payload_ever': True,
    #  'ggfg_tetrapeptide_linker': True, 'dar8_homogeneous': True,
    #  'dxd_bystander_killing': True,
    #  'destiny_breast03_pfs_hr_0_28': True}